Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959606 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL255454 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL8959930 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL9232946 | 0.94 | HTR2C (1.00) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959707 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959674 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959555 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959718 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959565 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL8959682 | 0.89 | HTR2C (0.79) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118176001-A | Methods for preventing and treating pain and related symptoms | 埃塞斯莫斯研究股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2023034293-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220226508-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-21 | — | — | US | disclosed |
| EP-3976187-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | The Regents of the University of California (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114007692-A | Methods and compositions for treating epilepsy | 加利福尼亚大学董事会 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226508-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | HTR2B, HTR3B, HTR1B | HTR2C 9/4885HTR2A 4/4885HTR2B 1/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR2C 72/4885HTR2A 28/4885HTR2B 4/4885 |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | KCNN3, KCNN2, KCNN1 | HTR2C 509/4885HTR2A 339/4885HTR2B 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.